BioCentury | Jan 25, 2020
Product Development

Radiotherapy blasts forward

...NSE:AUROPHARMA; BSE:524804) markets to treat non-Hodgkin’s lymphoma (NHL), and the iodine 131-labeled anti-CD20 mAb Bexxar tositumomab...
...and yttrium 90 -- have a longer clinical history going back to the Zevalin and Bexxar...
BioCentury | Sep 2, 2013
Company News

GlaxoSmithKline sales and marketing update

...GlaxoSmithKline will discontinue the manufacture and sale of cancer drug Bexxar tositumomab, effective Feb. 20, 2014...
...Feb. 20, 2014. The company said it decided to discontinue the product because "use of Bexxar...
...decline." GSK said there were "significant challenges related to the usage, reimbursement and recognition" of Bexxar...
BioCentury | Feb 14, 2011
Regulation

Decelerated approval

...run into trying to complete their confirmatory trials. The drugs included Arranon nelarabine and Bexxar tositumomab...
...cell leukemia and lymphoma. Clolar was approved in 2004 for pediatric acute lymphoblastic leukemia (ALL). Bexxar...
BioCentury | Jan 7, 2011
Politics & Policy

ODAC to discuss accelerated approval requirements

...not responded to or has relapsed following treatment with at least two prior chemotherapies; Bexxar tositumomab...
BioCentury | Mar 25, 2010
Cover Story

A B cell burden in prostate cancer

...radiolabeled antibodies for non-Hodgkin's lymphoma- Spectrum Pharmaceuticals Inc. 's Zevalin ibritumomab tiuxetan and GlaxoSmithKline's Bexxar tositumomab...
BioCentury | Jan 5, 2009
Company News

Genmab, GlaxoSmithKline deal

...Genmab declined to exercise its option to co-promote Arzerra ofatumumab, Bexar tositumomab and Arranon / Atriance...
BioCentury | Sep 24, 2007
Strategy

Genmab's commercial stockpile

...Drakeman told BioCentury. "Although we also have an option to carry two GSK products - Bexxar...
...Nordic countries, the territories that would be covered by a GSK-backed Genmab field force." Bexxar tositumomab...
BioCentury | Sep 24, 2007
Strategy

Asset accumulation

...Product Target Indication Status Atriance nelarabine (A) DNA synthesis Lymphoblastic leukemias Mkt (Nordic rights) Bexxar tositumomab...
BioCentury | Aug 13, 2007
Tools & Techniques

Dynamic dimerization

...June. Rituxan rituximab, Zevalin ibritumomab tiuxetan and Bexxar tositumomab are marketed anti-CD20 MAbs. Zevalin and Bexxar...
...BAY, Leverkusen, Germany) market Zevalin to treat NHL. GlaxoSmithKline plc (LSE:GSK; GSK, London, U.K.) markets Bexxar...
BioCentury | Jan 1, 2007
Company News

Genmab, GlaxoSmithKline deal

...that option, the company would also get the option to co-promote GSK's NHL drug Bexxar tositumomab...
Items per page:
1 - 10 of 232